[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _______ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Delaware 91-1949078 (State or other jurisd ...

Financial Performance - The company had no revenues for the years ended December 31, 2018, and December 31, 2017, remaining predominantly in the research and development stage [148]. - The net loss for the year ended December 31, 2018, was $18.0 million, an increase of approximately $3.2 million, or 22%, compared to a net loss of $14.8 million for the year ended December 31, 2017 [158]. - The company reported a net loss of $18.01 million for the year ended December 31, 2018, compared to a net loss of $14.77 million in 2017, indicating an increase in losses of about 22.5% [181]. - The company has incurred losses of approximately $73.7 million since inception and currently has no revenues, raising substantial doubt about its ability to continue as a going concern for at least one year from the issuance of the financial statements [191]. Operating Expenses - Total operating expenses increased to $17.9 million for the year ended December 31, 2018, from $14.7 million for the year ended December 31, 2017, representing a 22% increase [149]. - Operating expenses rose to $17.90 million in 2018, up from $14.70 million in 2017, reflecting an increase of approximately 21.5% [181]. - Research and development expenses rose to $10.9 million for the year ended December 31, 2018, up from $8.0 million in 2017, marking a 36% increase [150]. - The company incurred research and development expenses of $10.91 million in 2018, compared to $8.03 million in 2017, which is an increase of approximately 36.0% [181]. Cash and Liquidity - Cash and cash equivalents as of December 31, 2018, were approximately $13.4 million [137]. - Cash and cash equivalents at the end of 2018 were $13.43 million, an increase from $10.12 million at the end of 2017, marking a growth of about 32.5% [183]. - Net cash used in operating activities was approximately $14.7 million for the year ended December 31, 2018, compared to $12.2 million in 2017, reflecting increased expenditures on research and development and sales and marketing [138]. - Net cash used in operating activities was $14.73 million in 2018, compared to $12.19 million in 2017, indicating an increase of about 20.8% [183]. Financing Activities - Total cash provided by financing activities was approximately $18.0 million for the year ended December 31, 2018, compared to $2.0 million in 2017, primarily due to public offerings and private placements [140]. - The company plans to secure additional capital through grants, equity or debt financing, and licensing agreements to sustain operations [135]. - The company plans to secure additional funding through grants, debt or equity financing, licensing agreements, and accelerating product development to sustain operations [192]. - The company issued 8.8 million shares of common stock in 2018, raising net proceeds of $17.25 million compared to $0.998 million in 2017 [185]. Assets and Liabilities - As of December 31, 2018, total assets increased to $17.49 million from $14.62 million in 2017, representing a growth of approximately 19.5% [180]. - The total liabilities increased to $5.35 million in 2018 from $4.67 million in 2017, which is an increase of approximately 14.7% [180]. - The company’s accumulated deficit increased to $73.72 million in 2018 from $55.71 million in 2017, which is an increase of approximately 32.4% [180]. - The total stockholders' equity increased to $12.14 million in 2018 from $9.96 million in 2017, representing a growth of approximately 21.9% [180]. Shareholder Information - The weighted average shares outstanding increased to 31,389,220 in 2018 from 26,389,580 in 2017, reflecting an increase of approximately 19% [181]. - As of December 31, 2018, the company had 35,335,378 shares of common stock issued and outstanding, an increase from 26,519,394 shares as of December 31, 2017, representing a growth of approximately 33% [230]. - The company issued 3.5 million shares of common stock in a public offering at $2.40 per share, generating gross proceeds of $8.4 million and net proceeds of approximately $7.6 million after fees [231]. - In a private placement offering, the company issued 5.0 million shares at $1.80 per share, resulting in gross proceeds of $9.0 million and net proceeds of approximately $8.9 million [232]. Internal Controls - As of December 31, 2018, the Company did not maintain effective internal control over financial reporting due to material weaknesses identified [285]. - The identified material weaknesses included inadequate segregation of duties in Finance and insufficient oversight in IT and Human Resources [285]. - The Company is currently implementing a remediation plan to address the identified internal control deficiencies [287]. - Management believes that the material weaknesses did not affect the Company's financial results [285]. Future Outlook - The company provided an optimistic outlook for the next quarter, projecting revenue growth of BB% and an expected user base increase to CC million [305]. - New product launches are anticipated to contribute an additional $DD million in revenue, with a focus on innovative technologies [306]. - The company is expanding its market presence in Europe, targeting a market share increase of EE% by the end of the fiscal year [307]. - Recent acquisitions are expected to enhance operational capabilities and are projected to add $FF million in annual revenue [308].